Travere Therapeutics Inc (NAS:TVTX)
$ 6.16 -0.18 (-2.84%) Market Cap: 468.95 Mil Enterprise Value: 431.93 Mil PE Ratio: 0 PB Ratio: 6.33 GF Score: 54/100

Travere Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 17, 2022 / 12:30PM GMT
Release Date Price: $24.66 (+1.61%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Okay. Good morning, and welcome to day 3 of the Barclays Global Healthcare Conference. My name is Carter Gould, Senior Biopharma Analyst here at Barclays. Pleased to welcome Travere Therapeutics to the stage. Travere's got a very active 2022 ahead of itself with a number of key regulatory updates and hopefully some new launches. And joining us on stage right now are CEO, Eric Dube; and then Peter Heerma, Chief Commercial Officer. Chris Cline from the IR team is also around here, too. So Eric and Peter, thank you very much for joining us today.

Eric M. Dube
Travere Therapeutics, Inc. - President, CEO & Director

Thank you for hosting us.

Carter Lewis Gould;Eric M. Dube
Barclays Bank PLC, Research Division - Senior Analyst;

Before we jump into Q&A, why don't we just pass it over to you first to maybe make some opening comments and give a little background of the company and we set up the conversation.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot